
zzso increases zzso zzso cholesterol zzso levels through effects on zzso zzso transfer protein zzso As part of the zzso zzso clinical trial zzso the efficacy and safety of zzso is assessed in coronary heart disease zzso patients in the zzso study zzso zzso zzso the design and methods of which are presented zzso zzso DESIGN AND STUDY zzso Men and women with zzso or zzso risk zzso with zzso levels zzso zzso were recruited for a zzso zzso zzso zzso After a zzso phase of up to 8 weeks, patients received zzso zzso zzso or zzso in addition to their existing zzso zzso zzso zzso zzso measured by zzso ultrasound represents zzso function and is a validated marker for early zzso and cardiovascular disease zzso 

The primary efficacy outcome is change from baseline in zzso zzso after 12 zzso The primary safety zzso is 24-hour ambulatory blood pressure monitoring zzso assessed at week zzso Secondary zzso include zzso zzso at 36 weeks, zzso at 12 and 36 weeks, zzso profile, zzso mass and activity, and markers of zzso zzso and cardiovascular zzso Clinical zzso are assessed as a composite zzso for the zzso zzso 

In 19 European clinical zzso zzso subjects met inclusion criteria and have entered the zzso In conclusion, the zzso study is the largest zzso trial with zzso zzso ever zzso The study zzso efficacy and safety of zzso on zzso function, blood pressure, zzso and clinical outcomes in zzso patients with below average zzso and will therefore provide vital information regarding its potential role in the preventative treatment of zzso zzso 

